Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.380
-0.030 (-1.24%)
Mar 26, 2026, 12:59 PM EDT - Market open

Spero Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
134567891621567
Market Cap Growth
233.55%-27.82%-14.15%-85.38%9.38%207.32%
Enterprise Value
88.825.895.4-13.4528.55447.34
Last Close Price
2.381.031.471.7316.0119.39
PE Ratio
--0.813.42-1.41-5.50-5.51
PS Ratio
3.311.170.751.7033.9960.81
PB Ratio
5.121.220.731.207.034.30
P/TBV Ratio
4.991.210.730.865.603.29
P/FCF Ratio
--2.40-2.36-11.74-9.64-6.59
P/OCF Ratio
--2.40-2.36-11.74-9.64-6.61
EV/Sales Ratio
2.190.120.05-0.2528.9547.95
EV/EBITDA Ratio
--0.080.250.32-6.05-5.71
EV/EBIT Ratio
--0.080.250.32-6.01-5.65
EV/FCF Ratio
--0.25-0.161.73-8.21-5.20
Debt / Equity Ratio
0.050.060.040.070.620.05
Debt / EBITDA Ratio
-0.07-0.060.25-0.16-0.64-0.10
Debt / FCF Ratio
-0.12-0.18-0.17-0.86-0.87-0.09
Net Debt / Equity Ratio
-1.71-1.05-0.66-1.35-1.03-0.90
Net Debt / EBITDA Ratio
0.970.66-3.242.481.041.52
Net Debt / FCF Ratio
1.642.072.1513.251.411.38
Asset Turnover
0.490.330.680.360.110.07
Quick Ratio
3.742.154.675.097.989.28
Current Ratio
3.832.193.535.258.469.70
Return on Equity (ROE)
-119.13%-89.62%30.63%-56.53%-81.47%-75.77%
Return on Assets (ROA)
-56.47%-50.09%15.42%-28.52%-54.22%-60.96%
Return on Invested Capital (ROIC)
-321.01%-112.22%45.44%-550.73%-786.58%-1379.24%
Return on Capital Employed (ROCE)
-91.81%-70.98%17.30%-33.02%-60.36%-72.40%
Earnings Yield
-32.69%-123.30%29.25%-71.10%-18.18%-18.15%
FCF Yield
-20.64%-41.69%-42.35%-8.52%-10.37%-15.16%
Buyback Yield / Dilution
-0.00%-0.28%-27.47%-13.95%-14.25%
Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q